Vascular function and Antiplatelet effects on switching from Clopidgrel to Prasugrel in chronic phase after percutaneous coronary interventio
Not Applicable
- Conditions
- The patients on DAPT after PCI who underwent follow-up coronary angiography
- Registration Number
- JPRN-UMIN000023756
- Lead Sponsor
- Department of Cardiovascular Medicine,Dokkyo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1:Ptients who has high risk for bleeding 2:Patients with heart Valve Disease and congenital heart disease 3:Patients with cerebrovascular disease 4:Patients who have infection or Inflammatory disease 5:Patients with malignant neoplasm 6:CKD <G4 eGFR<30(ml/min/1.7m2) 7:Patients with allergy against thienopyridines 8:Patients undergoing anticoagulation therapy 9:Patients who are not suitable for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of change on PRU from baseline to observation point(6M+-3M) between Clopidgrel with Aspirin and Prasugrel with Aspirin
- Secondary Outcome Measures
Name Time Method 1:The effect of CYP2C19 polymorphism against the PRU from baseline to observation point between Clopidgrel with Aspirin and Prasugrel with Aspirin 2:Quantitative change on FMD from baseline to observation point between Clopidgrel with Aspirin and Prasugrel with Aspirin 3:Quantitative change on RHI from baseline to observation point between Clopidgrel with Aspirin and Prasugrel with Aspirin 4:Quantitative change and rate of change on Inflammatory biomarkers from baseline to observation point between Clopidgrel with Aspirin and Prasugrel with Aspirin 5:Quantitative change on CD34+/CD133+/CD45low cells from baseline to observation point between Clopidgrel with Aspirin and Prasugrel with Aspirin